Stocktoria
KalVista Pharmaceuticals, Inc. KALV
KalVista Pharmaceuticals, Inc. (KALV) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Manufacturing · percentile among 1906 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.784 |
| Retained earnings / assets | -2.605 |
| EBIT / assets | -0.75 |
| Equity / liabilities | 0.614 |
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | 1/9 | -7.74 | — | +294% |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
FAQ
Is KALV financially healthy?
KalVista Pharmaceuticals, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does KALV pay a dividend?
No, KalVista Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is KALV?
In FY2025, KalVista Pharmaceuticals, Inc. had a return on equity of -192.3%.
Source: SEC EDGAR filings · CIK 0001348911 · US · as of 2025-04-30. facts plus Stocktoria's own computed scores — not investment advice.